IEMbase 0374: ANGPTL3-related angiopoietin-like 3 deficiency
Scope
| Field | Value |
|---|---|
| IEMbase ID | 374 |
| Nosology | 15.5.1.01 |
| Gene | ANGPTL3 |
| External IDs | OMIM:605019; OMIM:604774 |
| Generated mapping | MAPPED; Abetalipoproteinemia.yaml |
| Candidate DisMech targets | No exact local target; Abetalipoproteinemia.yaml is shared hypolipidemia context only |
| Review date | 2026-07-07 |
IEMbase phenotype signal
IEMbase represents ANGPTL3-related angiopoietin-like 3 deficiency, with alternate names familial hypobetalipoproteinemia type 2 and combined familial hypolipidemia. Inheritance is autosomal recessive.
The cached record is clinically sparse and states no clinical significance. Biochemical rows include plasma HDL cholesterol, plasma LDL cholesterol, serum triglyceride, and plasma Apo B. There are no treatment rows.
DisMech phenotype coverage
The generated mapping to Abetalipoproteinemia.yaml is a false positive exact
mapping driven by shared hypobetalipoproteinemia identifiers or labels. Local
abetalipoproteinemia models MTTP-related failure of apoB-lipoprotein assembly,
not ANGPTL3 deficiency.
The Familial Hypercholesterolemia file discusses ANGPTL3 as a therapeutic target through evinacumab in homozygous FH, but this is drug-target context for LDL lowering, not a curated ANGPTL3 deficiency disease.
Concordance and completeness
Judgement: false positive exact mapping; ANGPTL3-related combined familial hypolipidemia is a local disease gap or scope-review item.
IEMbase and abetalipoproteinemia share low LDL, low triglyceride, low HDL, and low Apo B biochemical directionality, but the causal mechanism differs. ANGPTL3 loss affects lipoprotein lipase and endothelial lipase inhibition, whereas the local abetalipoproteinemia file models MTTP loss and apoB-lipoprotein export failure.
Curation actions
- Do not treat
Abetalipoproteinemia.yamlas the exact target for this record. - Create or prioritize a separate ANGPTL3 combined familial hypolipidemia entry if this low-LDL condition is in DisMech scope.
- Keep local FH/evinacumab ANGPTL3 content as therapeutic pathway context only.
- Review the IEMbase "no clinical significance" row before deciding disease scope and phenotype import.